Video
ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer wi...
Dr Virginia G. Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San ...
ASCO 2022: Breast cancer highlights
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer
Dr Etienne Brain - Institut Curie, Paris, France
Safety follow-up of the randomized, phase 3 study DESTINY-Breast03
Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA
Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 exp...
Dr Shanu Modi - Memorial Sloan Kettering Cancer Centre, Manhattan, USA
Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic b...
Dr Jane Lowe Meisel- Winship Cancer Institute of Emory University, Georgia, USA
Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast can...
Shanu Modi- Memorial Sloan Ketting Cancer Center, Manhattan, USA
Sacituzumab goviteca provides clinically meaningful PFS benefit for hormone rece...
Dr Hope Rugo - University of California San Francisco, San Francisco, USA
Comment: Sacituzumab govitecan for HR+/HER2‐ advanced breast cancer
Dr Jane Lowe Meisel - Winship Cancer Institute of Emory University, Georgia, USA
Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer
Dr Hope Rugo - University of California San Francisco, San Francisco, USA
Cancer Services Delivery: Focus on India
Dr Soumitra Datta - Tata Medical Center, Kolkata, India
Diagnostic performance and survival outcome of SLNB procedure in breast cancer p...
Dr Sanjit Kumar Agrawal - Tata Medical Center, Kolkata, India